2021 September 23
1.
Prevalence of multiple sclerosis in key cities of Brazil: a study in Passo Fundo, Southern Brazil. Passos GRD, Becker J, Varela DL, Fröhlich AC, Rech BC, Mattos ACS, Callegaro D, Lana-Peixoto MA.
Arq Neuropsiquiatr. 2021 Aug;79(8):692-696. doi: 10.1590/0004-282X-anp-2020-0221.
PMID: 34550189
2.
Regional brain atrophy is related to social cognition impairment in multiple sclerosis. Labbe TP, Montalba C, Zurita M, Ciampi EL, Cruz JP, Vasquez M, Uribe S, Crossley N, Cárcamo C.
Arq Neuropsiquiatr. 2021 Aug;79(8):666-675. doi: 10.1590/0004-282X-anp-2020-0162.
PMID: 34550187
3.
Ponesimod (Ponvory) for multiple sclerosis. [No authors listed]
Med Lett Drugs Ther. 2021 Aug 9;63(1630):123-125.
PMID: 34550110 No abstract available.
4.
Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. Weber CE, Krämer J, Wittayer M, Gregori J, Randoll S, Weiler F, Heldmann S, Roßmanith C, Platten M, Gass A, Eisele P.
Eur Radiol. 2021 Sep 22. doi: 10.1007/s00330-021-08233-w. Online ahead of print.
PMID: 34549326
5.
Are Fungal Pathogens Manipulating Human Behavior? Frost P.
Perspect Biol Med. 2020;63(4):591-601. doi: 10.1353/pbm.2020.0059.
PMID: 33416798
2021 September 22
1.
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Correale J, Halfon MJ, Jack D, Rubstein A, Villa A.
Mult Scler Relat Disord. 2021 Sep 14;56:103264. doi: 10.1016/j.msard.2021.103264. Online ahead of print.
PMID: 34547609
2.
Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. Molazadeh N, Filippatou AG, Vasileiou ES, Levy M, Sotirchos ES.
J Neuroimmunol. 2021 Aug 26;360:577702. doi: 10.1016/j.jneuroim.2021.577702. Online ahead of print.
PMID: 34547512 Review.
3.
Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E.
J Neuroimmunol. 2021 Sep 15;360:577721. doi: 10.1016/j.jneuroim.2021.577721. Online ahead of print.
PMID: 34547511 Review.
4.
New concepts on immunology of Multiple Sclerosis. Couloume L, Michel L.
Presse Med. 2021 Sep 18:104072. doi: 10.1016/j.lpm.2021.104072. Online ahead of print.
PMID: 34547375
5.
Cerebrospinal fluid levels of L-glutamate signal central inflammatory neurodegeneration in multiple sclerosis. Stampanoni Bassi M, Nuzzo T, Gilio L, Miroballo M, Casamassa A, Buttari F, Bellantonio P, Fantozzi R, Galifi G, Furlan R, Finardi A, De Rosa A, Di Maio A, Errico F, Centonze D, Usiello A.
J Neurochem. 2021 Sep 21. doi: 10.1111/jnc.15518. Online ahead of print.
PMID: 34547109
6.
Dry needling for the treatment of muscle spasticity in a patient with multiple sclerosis: a case report. Khalifeloo M, Naghdi S, Ansari NN, Dommerholt J, Sahraian MA.
Physiother Theory Pract. 2021 Sep 21:1-7. doi: 10.1080/09593985.2021.1978118. Online ahead of print.
PMID: 34546842
7.
Association of cholesterol 7α-hydroxylase (CYP7A1) promoter polymorphism (rs3808607) and cholesterol 24S-hydroxylase (CYP46A1) intron 2 polymorphism (rs754203) with serum lipids, vitamin D levels, and multiple sclerosis risk in the Turkish population. Sezer E, Can Demirdöğen B, Demirkaya Ş, Bulut G, Akkulak M, Evin E, Adalı O.
Neurol Sci. 2021 Sep 21. doi: 10.1007/s10072-021-05597-1. Online ahead of print.
PMID: 34546511
8.
Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA. Wu D, Chen D, Shi W, Liu W, Zhou W, Qian J.
Can J Gastroenterol Hepatol. 2021 Sep 10;2021:9936932. doi: 10.1155/2021/9936932. eCollection 2021.
PMID: 34545326 Free PMC article.
9.
Positron emission tomography in multiple sclerosis – straight to the target. Bodini B, Tonietto M, Airas L, Stankoff B.
Nat Rev Neurol. 2021 Sep 20. doi: 10.1038/s41582-021-00537-1. Online ahead of print.
PMID: 34545219 Review.
10.
Nasogastric tube insertion in intubated patients with the guide of wire rope: A prospective randomised controlled study. Sharifnia HR, Jahangiri S, Majidi F, Shariat Moharari R, Shahmirzaei S, Khajavi MR.
Int J Clin Pract. 2021 Oct;75(10):e14508. doi: 10.1111/ijcp.14508. Epub 2021 Jun 23.
PMID: 34118103 Clinical Trial.
11.
Seizures and memory impairment induced by patient-derived anti-N-methyl-D-aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin-1 receptor antagonist. Taraschenko O, Fox HS, Zekeridou A, Pittock SJ, Eldridge E, Farukhuddin F, Al-Saleem F, Devi Kattala C, Dessain SK, Casale G, Willcockson G, Dingledine R.
Epilepsia. 2021 Mar;62(3):671-682. doi: 10.1111/epi.16838. Epub 2021 Feb 17.
PMID: 33596332
September 21
1.
Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed. Naser Moghadasi A.
Mult Scler Relat Disord. 2021 Sep 13;56:103263. doi: 10.1016/j.msard.2021.103263. Online ahead of print.
PMID: 34543859 No abstract available.
2.
Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. Lizarraga AA, Rammohan KW, Weinstock-Guttman B, Sharma K.
Mult Scler Relat Disord. 2021 Sep 4;56:103254. doi: 10.1016/j.msard.2021.103254. Online ahead of print.
PMID: 34543858
3.
MicroRNA-7188-5p and miR-7235 regulates Multiple sclerosis in an experimental mouse model. Ibrahim HM, AlZahrani A, Hanieh H, Ahmed EA, Thirugnanasambantham K.
Mol Immunol. 2021 Sep 17;139:157-167. doi: 10.1016/j.molimm.2021.07.002. Online ahead of print.
PMID: 34543842
4.
Do people with multiple sclerosis receive appropriate support from the National Disability Insurance Scheme matching their level of disability? A description of disease ‚burden and societal cost in people with multiple sclerosis in Australia. Lechner-Scott J, Reeves P, Ribbons K, Saugbjerg B, Lea R.
Aust Health Rev. 2021 Sep 21. doi: 10.1071/AH21056. Online ahead of print.
PMID: 34543604
5.
Potent T cell mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. Tiberi M, Evron T, Saracini S, Boffa L, Mercuri NB, Chintalacharuvu SR, Atamas SP, Chiurchiù V.
Neuropathol Appl Neurobiol. 2021 Sep 20. doi: 10.1111/nan.12768. Online ahead of print.
PMID: 34543449
6.
Propagating Uncertainty Across Cascaded Medical Imaging Tasks For Improved Deep Learning Inference. Mehta R, Christinck T, Nair T, Bussy A, Premasiri S, Costantino M, Chakravarty M, Arnold DL, Gal Y, Arbel T.
IEEE Trans Med Imaging. 2021 Sep 20;PP. doi: 10.1109/TMI.2021.3114097. Online ahead of print.
PMID: 34543193
7.
Assessment of Artificial Intelligence Automatic Multiple Sclerosis Lesion Delineation Tool for Clinical Use. Hindsholm AM, Cramer SP, Simonsen HJ, Frederiksen JL, Andersen F, Højgaard L, Ladefoged CN, Lindberg U.
Clin Neuroradiol. 2021 Sep 20. doi: 10.1007/s00062-021-01089-z. Online ahead of print.
PMID: 34542644
8.
The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Lewis JE, Poles J, Shaw DP, Karhu E, Khan SA, Lyons AE, Sacco SB, McDaniel HR.
J Clin Transl Res. 2021 Aug 4;7(4):575-620. eCollection 2021 Aug 26.
PMID: 34541370 Free PMC article. Review.
9.
Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity. Mandel LA, O’Donnell E, Canenguez K, Castro-Mendoza PB, Lotze T, Waubant E, Weinstock-Guttmann B, Chitnis T.
J Patient Exp. 2021 Sep 15;8:23743735211039319. doi: 10.1177/23743735211039319. eCollection 2021.
PMID: 34541304 Free PMC article.
10.
Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score. Ebenau JL, van der Lee SJ, Hulsman M, Tesi N, Jansen IE, Verberk IMW, van Leeuwenstijn M, Teunissen CE, Barkhof F, Prins ND, Scheltens P, Holstege H, van Berckel BNM, van der Flier WM.
Alzheimers Dement (Amst). 2021 Sep 14;13(1):e12229. doi: 10.1002/dad2.12229. eCollection 2021.
PMID: 34541285 Free PMC article.
11.
Tuberous sclerosis complex-lymphangioleiomyomatosis involving several visceral organs: A case report. Chen HB, Xu XH, Yu CG, Wan MT, Feng CL, Zhao ZY, Mei DE, Chen JL.
World J Clin Cases. 2021 Aug 26;9(24):7085-7091. doi: 10.12998/wjcc.v9.i24.7085.
PMID: 34540963 Free PMC article.
12.
Shear wave elastography in optic neuritis: diagnostic accuracy of the optic nerve and adjacent fat tissue values. Aybar MD, Turna O.
J Ultrason. 2021 Aug 16;21(86):e194-e199. doi: 10.15557/JoU.2021.0031. Epub 2021 Sep 9.
PMID: 34540272 Free PMC article.
13.
Erratum to „A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod“. [No authors listed]
Ther Adv Neurol Disord. 2021 Sep 14;14:17562864211044631. doi: 10.1177/17562864211044631. eCollection 2021.
PMID: 34539815 Free PMC article.
14.
Quantitative 7-Tesla Imaging of Cortical Myelin Changes in Early Multiple Sclerosis. Barletta V, Herranz E, Treaba CA, Mehndiratta A, Ouellette R, Mangeat G, Granberg T, Sloane JA, Klawiter EC, Cohen-Adad J, Mainero C.
Front Neurol. 2021 Sep 3;12:714820. doi: 10.3389/fneur.2021.714820. eCollection 2021.
PMID: 34539559 Free PMC article.
15.
The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. Lorefice L, Casaglia E, Fronza M, Frau J, Fenu G, Pilotto S, Coghe G, Barracciu MA, Cocco E.
Front Neurol. 2021 Sep 1;12:679355. doi: 10.3389/fneur.2021.679355. eCollection 2021.
PMID: 34539545 Free PMC article.
16.
Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via Spray-Drying Enhances Their Uptake in the Olfactory Mucosa. Spindler LM, Feuerhake A, Ladel S, Günday C, Flamm J, Günday-Türeli N, Türeli E, Tovar GEM, Schindowski K, Gruber-Traub C.
Front Pharmacol. 2021 Sep 1;12:732954. doi: 10.3389/fphar.2021.732954. eCollection 2021.
PMID: 34539414 Free PMC article.
17.
CONFISEP: Impact of the Covid-19 pandemic lockdown on patients with multiple sclerosis in the north of France. Donzé C, Massot C, Kwiatkowski A, Guenot M, Hautecoeur P.
Rev Neurol (Paris). 2021 Sep 11:S0035-3787(21)00651-2. doi: 10.1016/j.neurol.2021.09.001. Online ahead of print.
PMID: 34538668
18.
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Saketkoo LA, Frech T, Varjú C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkmann ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirják L, Jensen K, Hinchclif M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, Steen V.
Best Pract Res Clin Rheumatol. 2021 Sep 15:101707. doi: 10.1016/j.berh.2021.101707. Online ahead of print.
PMID: 34538573 Review.
19.
Exercise and Sports Science Australia (ESSA) position statement on exercise for people with mild to moderate multiple sclerosis. Hoang PD, Lord S, Gandevia S, Menant J.
J Sci Med Sport. 2021 Aug 24:S1440-2440(21)00214-0. doi: 10.1016/j.jsams.2021.08.015. Online ahead of print.
PMID: 34538565
20.
Biological sex as a critical variable in CD4+ effector T cell function in preclinical models of multiple sclerosis. Umair M, Fazazi MR, Rangachari M.
Antioxid Redox Signal. 2021 Sep 20. doi: 10.1089/ars.2021.0202. Online ahead of print.
PMID: 34538129
21.
MicroRNA-22 Level in Patients with Multiple Sclerosis and Its Relationship with Vitamin D and Vitamin D Receptor Levels. Khedr AMB, Shaker OG, Hassan A, Hussein M, Kamal YS, Azouz TA.
Neuroimmunomodulation. 2021 Sep 17:1-7. doi: 10.1159/000519012. Online ahead of print.
PMID: 34537762
22.
The utility of Magnetoencephalography in multiple sclerosis – A systematic review. Khan H, Sami MB, Litvak V.
Neuroimage Clin. 2021 Sep 9;32:102814. doi: 10.1016/j.nicl.2021.102814. Online ahead of print.
PMID: 34537682 Review.
23.
Does the venous pressure theory of multiple sclerosis pathophysiology deserve a second chance? Bateman GA, Lechner-Scott J, Carey MF, Bateman AR, Lea RA.
Mult Scler Relat Disord. 2021 Sep 13;56:103262. doi: 10.1016/j.msard.2021.103262. Online ahead of print.
PMID: 34537585
24.
Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction. Minozzi S, Dwan K, Borrelli F, Filippini G.
J Clin Epidemiol. 2021 Sep 16:S0895-4356(21)00307-3. doi: 10.1016/j.jclinepi.2021.09.021. Online ahead of print.
PMID: 34537386
25.
How major fungal infections can initiate severe autoimmune diseases. Roe K.
Microb Pathog. 2021 Sep 16:105200. doi: 10.1016/j.micpath.2021.105200. Online ahead of print.
PMID: 34537272 Review.
26.
Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community. Vázquez-Costa JF, Martínez-Molina M, Fernández-Polo M, Fornés-Ferrer V, Frasquet-Carrera M, Sevilla-Mantecón T.
Neurologia (Engl Ed). 2021 Sep;36(7):504-513. doi: 10.1016/j.nrleng.2018.03.023. Epub 2020 Jun 3.
PMID: 34537164
27.
The influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosis. Castillo-Álvarez F, Pérez-Matute P, Oteo JA, Marzo-Sola ME.
Neurologia (Engl Ed). 2021 Sep;36(7):495-503. doi: 10.1016/j.nrleng.2020.05.006. Epub 2020 May 31.
PMID: 34537163
28.
Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. Freedman MS, Wojcik J, Holmberg KH, Fluck M, D’Antonio M, Hyvert Y, Stinchi S, D’Urso V, Dangond F.
J Neuroimmunol. 2021 Sep 9;360:577715. doi: 10.1016/j.jneuroim.2021.577715. Online ahead of print.
PMID: 34536787
29.
Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. Shahmohammadi S, Doosti R, Shahmohammadi A, Azimi A, Sahraian MA, Fattahi MR, Naser Moghadasi A.
Mult Scler Relat Disord. 2021 Aug 27;56:103227. doi: 10.1016/j.msard.2021.103227. Online ahead of print.
PMID: 34536774 Review.
30.
Genetically predicted circulating homocysteine, vitamin B12, and folate levels and risk of multiple sclerosis: evidence from a two-sample Mendelian randomization analysis. Peng H, Wu X, Lin J, Guan W.
Mult Scler Relat Disord. 2021 Sep 5;56:103255. doi: 10.1016/j.msard.2021.103255. Online ahead of print.
PMID: 34536773
31.
Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study. Pérez CA, Lincoln JA.
Mult Scler Relat Disord. 2021 Sep 9;56:103248. doi: 10.1016/j.msard.2021.103248. Online ahead of print.
PMID: 34536772
32.
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle. Chidambaram SB, Essa MM, Rathipriya AG, Bishir M, Ray B, Mahalakshmi AM, Tousif AH, Sakharkar MK, Kashyap RS, Friedland R, Monaghan TM.
Pharmacol Ther. 2021 Sep 15:107988. doi: 10.1016/j.pharmthera.2021.107988. Online ahead of print.
PMID: 34536490 Review.
33.
A new strategy to increase RNA Editing at the Q/R Site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2. Chaytow H, Hassan IS, Akbar S, Popplewell L, Dickson G, Chen PE.
J Neurosci Methods. 2021 Sep 15:109357. doi: 10.1016/j.jneumeth.2021.109357. Online ahead of print.
PMID: 34536489
34.
Retinoids are not linked to risk of Multiple Sclerosis: a Danish nationwide cohort study. Cortes-Figueiredo F, Nielsen NM, Stenager E, Paul F, Hallas J, Kristensen KB.
Eur J Neurol. 2021 Sep 18. doi: 10.1111/ene.15116. Online ahead of print.
PMID: 34536255
35.
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand’Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pfleger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators.
CNS Drugs. 2021 Sep 18. doi: 10.1007/s40263-021-00860-7. Online ahead of print.
PMID: 34536228
36.
Emerging therapeutic opportunities for integrin inhibitors. Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD.
Nat Rev Drug Discov. 2021 Sep 17:1-19. doi: 10.1038/s41573-021-00284-4. Online ahead of print.
PMID: 34535788 Free PMC article. Review.
37.
Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study. McKay KA, Wickström R, Hillert J, Karrenbauer VD.
Sci Rep. 2021 Sep 17;11(1):18528. doi: 10.1038/s41598-021-97543-6.
PMID: 34535701
38.
Pericyte-derived fibrotic scarring is conserved across diverse central nervous system lesions. Dias DO, Kalkitsas J, Kelahmetoglu Y, Estrada CP, Tatarishvili J, Holl D, Jansson L, Banitalebi S, Amiry-Moghaddam M, Ernst A, Huttner HB, Kokaia Z, Lindvall O, Brundin L, Frisén J, Göritz C.
Nat Commun. 2021 Sep 17;12(1):5501. doi: 10.1038/s41467-021-25585-5.
PMID: 34535655
39.
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis. Cruciani C, Puthenparampil M, Tomas-Ojer P, Jelcic I, Docampo MJ, Planas R, Manogaran P, Opfer R, Wicki C, Reindl M, Jelcic I, Lutterotti A, Martin R, Sospedra M.
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 17;8(6):e1075. doi: 10.1212/NXI.0000000000001075. Print 2021 Nov.
PMID: 34535569
40.
Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine-1 Phosphate Receptor Subtypes 1 and 5. Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R.
J Pharmacol Exp Ther. 2021 Sep 17:JPET-AR-2021-000741. doi: 10.1124/jpet.121.000741. Online ahead of print.
PMID: 34535564
41.
Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis. Rice J, Xiang XM.
Neurology. 2021 Aug 31;97(9):e972-e974. doi: 10.1212/WNL.0000000000012510. Epub 2021 Aug 30.
PMID: 34534101 No abstract available.
42.
Tuberous Sclerosis: Current Update. Wang MX, Segaran N, Bhalla S, Pickhardt PJ, Lubner MG, Katabathina VS, Ganeshan D.
Radiographics. 2021 Sep 17:210103. doi: 10.1148/rg.2021210103. Online ahead of print.
PMID: 34534018
43.
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C.
J Neurol. 2021 Sep 17:1-7. doi: 10.1007/s00415-021-10803-3. Online ahead of print.
PMID: 34533590 Free PMC article.
44.
Machine learning to investigate superficial white matter integrity in early multiple sclerosis. Buyukturkoglu K, Vergara C, Fuentealba V, Tozlu C, Dahan JB, Carroll BE, Kuceyeski A, Riley CS, Sumowski JF, Oliva CG, Sitaram R, Guevara P, Leavitt VM.
J Neuroimaging. 2021 Sep 17. doi: 10.1111/jon.12934. Online ahead of print.
PMID: 34532924
45.
Extensor plantar response elicited by neck extension. Estañol B, Mendizábal-Méndez JL, Delgado-García G.
Acta Neurol Belg. 2021 Sep 16. doi: 10.1007/s13760-021-01803-1. Online ahead of print.
PMID: 34532827 No abstract available.
46.
Therapeutic Targeting of Immune Cell Autophagy in Multiple Sclerosis: Russian Roulette or Silver Bullet? Yang G, Van Kaer L.
Front Immunol. 2021 Aug 31;12:724108. doi: 10.3389/fimmu.2021.724108. eCollection 2021.
PMID: 34531871 Free PMC article. Review.
47.
The Emerging World of Microbiome in Autoimmune Disorders: Opportunities and Challenges. Mangalam AK, Yadav M, Yadav R.
Indian J Rheumatol. 2021 Mar;16(1):57-72. doi: 10.4103/injr.injr_210_20. Epub 2021 Mar 23.
PMID: 34531642 Free PMC article.
48.
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis. Pontillo G, Tommasin S, Cuocolo R, Petracca M, Petsas N, Ugga L, Carotenuto A, Pozzilli C, Iodice R, Lanzillo R, Quarantelli M, Brescia Morra V, Tedeschi E, Pantano P, Cocozza S.
AJNR Am J Neuroradiol. 2021 Sep 16. doi: 10.3174/ajnr.A7274. Online ahead of print.
PMID: 34531195
49.
Advantages of using the optic nerve ecography to predict clinical progression in multiple sclerosis. Guzman I, Gomez R.
Neurologia. 2021 Sep 13:S0213-4853(21)00119-5. doi: 10.1016/j.nrl.2021.07.001. Online ahead of print.
PMID: 34531046 English, Spanish. No abstract available.
50.
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Carnero Contentti E, Correale J.
J Neuroinflammation. 2021 Sep 16;18(1):208. doi: 10.1186/s12974-021-02249-1.
PMID: 34530847 Free PMC article. Review.
2021 September 16
1.
Medical management of heavily exposed victims: An experience at the Tokaimura criticality accident. Akashi M, Maekawa K.
J Radiol Prot. 2021 Sep 15. doi: 10.1088/1361-6498/ac270d. Online ahead of print.
PMID: 34525457
2.
ACKR1 favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier in neuroinflammation in vitro. Marchetti L, Francisco D, Soldati S, Jahromi NH, Barcos S, Gruber I, Pareja JR, Thiriot A, von Andrian U, Deutsch U, Lyck R, Bruggmann R, Engelhardt B.
Eur J Immunol. 2021 Sep 15. doi: 10.1002/eji.202149238. Online ahead of print.
PMID: 34524684
3.
[Paroxysmal dysarthria and ataxia – unusual MS manifestation]. Papastergios C, Shaker A, Schiopu-Mariean BL, Morar F.
Lakartidningen. 2021 Sep 15;118:21022.
PMID: 34524683 Swedish.
4.
Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. Lo SH, Marshall J, Skrobanski H, Lloyd A.
Pharmacoecon Open. 2021 Sep 15. doi: 10.1007/s41669-021-00296-1. Online ahead of print.
PMID: 34524653
5.
Correction to: Optic neuritis in German children: clinical findings and association with multiple sclerosis. Tonagel F, Wilhelm H, Kelbsch C.
Graefes Arch Clin Exp Ophthalmol. 2021 Sep 15. doi: 10.1007/s00417-021-05343-5. Online ahead of print.
PMID: 34524499 No abstract available.
6.
Identification of causal metabolites related to multiple autoimmune diseases. Yu XH, Cao RR, Yang YQ, Lei SF.
Hum Mol Genet. 2021 Sep 15:ddab273. doi: 10.1093/hmg/ddab273. Online ahead of print.
PMID: 34523675
7.
Graves‘ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis. Duarte DB, Silva AMD, Freitas C, Cardoso H.
Endocr Regul. 2021 Sep 13;55(3):169-173. doi: 10.2478/enr-2021-0018.
PMID: 34523298
8.
Tension and trauma releasing exercises for people with multiple sclerosis – An exploratory pilot study. Lynning M, Svane C, Westergaard K, Bergien SO, Gunnersen SR, Skovgaard L.
J Tradit Complement Med. 2021 Feb 8;11(5):383-389. doi: 10.1016/j.jtcme.2021.02.003. eCollection 2021 Sep.
PMID: 34522632 Free PMC article.
9.
Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report. Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E.
Sultan Qaboos Univ Med J. 2021 Aug;21(3):488-490. doi: 10.18295/squmj.4.2021.021. Epub 2021 Aug 29.
PMID: 34522419 Free PMC article.
10.
Acute onset anarthria in a 7-year-old patient as a presentation of acute disseminated encephalomyelitis: A rare clinical and radiological entity. Belfkih R, Khayat OG.
Radiol Case Rep. 2021 Sep 4;16(11):3418-3421. doi: 10.1016/j.radcr.2021.08.016. eCollection 2021 Nov.
PMID: 34522279 Free PMC article.
11.
The Impact of Motor Disability and the Level of Fatigue on Adherence to Therapeutic Recommendations in Patients with Multiple Sclerosis Treated with Immunomodulation. Ślusarz R, Olkiewicz J, Bonek R, Filipska K, Biercewicz M, Wiśniewski A.
Int J Med Sci. 2021 Aug 27;18(15):3609-3614. doi: 10.7150/ijms.61964. eCollection 2021.
PMID: 34522188 Free PMC article.
12.
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM, E Markowitz C, Mexhitaj I, Jacobs D, Babb A, Betts MR, Prak ETL, Weiskopf D, Grifoni A, Lundgreen KA, Gouma S, Sette A, Bates P, Hensley SE, Greenplate AR, Wherry EJ, Li R, Bar-Or A.
Nat Med. 2021 Sep 14. doi: 10.1038/s41591-021-01507-2. Online ahead of print.
PMID: 34522051
13.
Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Tintore M, Cobo-Calvo A, Carbonell P, Arrambide G, Otero-Romero S, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Zabalza A, Salerno A, Auger C, Sastre-Garriga J, Rovira À, Montalban X.
Neurology. 2021 Sep 14:10.1212/WNL.0000000000012726. doi: 10.1212/WNL.0000000000012726. Online ahead of print.
PMID: 34521693
14.
Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis. Tobin O.
Neurology. 2021 Sep 14:10.1212/WNL.0000000000012738. doi: 10.1212/WNL.0000000000012738. Online ahead of print.
PMID: 34521689 No abstract available.
2021 September 15
1.
Tensor electrical impedance myography identifies clinically relevant features in amyotrophic lateral sclerosis. Schooling CN, Healey TJ, McDonough HE, French SJ, McDermott CJ, Shaw PJ, Kadirkamanathan V, Alix JJP.
Physiol Meas. 2021 Sep 14. doi: 10.1088/1361-6579/ac2672. Online ahead of print.
PMID: 34521070
2.
Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Mehmood A, Ali W, Song S, Din ZU, Guo RY, Shah W, Ilahi I, Yin B, Yan H, Zhang L, Khan M, Ali W, Zeb L, Safari H, Li B.
Brain Behav. 2021 Sep 14:e32302. doi: 10.1002/brb3.2302. Online ahead of print.
PMID: 34520634 Review.
3.
Systematic Review of Exercise Studies in Persons with Multiple Sclerosis: Exploring the Quality of Interventions According to the Principles of Exercise Training. Schlagheck ML, Joisten N, Walzik D, Wolf F, Neil-Sztramko SE, Bansi J, Rademacher A, Zimmer P.
Neurol Ther. 2021 Sep 14. doi: 10.1007/s40120-021-00274-z. Online ahead of print.
PMID: 34520000 Review.
4.
Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier. Rhea EM, Banks WA.
Pharm Res. 2021 Sep 13. doi: 10.1007/s11095-021-03098-6. Online ahead of print.
PMID: 34518942
5.
Rate-dependent depression is impaired in amyotrophic lateral sclerosis. Zhou X, Wang Z, Lin Z, Zhu Y, Zhu D, Xie C, Calcutt NA, Guan Y.
Neurol Sci. 2021 Sep 13. doi: 10.1007/s10072-021-05596-2. Online ahead of print.
PMID: 34518934
6.
Teriflunomide, a potential novel cause of chronic active colitis. Kővári B, Zachs J, Murchie B, Lauwers GY.
Histopathology. 2020 Dec;77(6):1000-1001. doi: 10.1111/his.14122. Epub 2020 Oct 7.
PMID: 32323888 No abstract available.
2021 September 14
1.
Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. Parks NE, Andreou P, Marrie RA, Fisk JD, Bhan V, Kirkland SA.
Mult Scler Relat Disord. 2021 Sep 4;56:103249. doi: 10.1016/j.msard.2021.103249. Online ahead of print.
PMID: 34517192
2.
Deep brain stimulation for multiple sclerosis tremor: A systematic review and meta-analysis. Zali A, Khoshnood RJ, Motavaf M, Salimi A, Akhlaghdoust M, Safari S, Ghajarzadeh M, Mirmosayyeb O.
Mult Scler Relat Disord. 2021 Sep 6;56:103256. doi: 10.1016/j.msard.2021.103256. Online ahead of print.
PMID: 34517191 Review.
3.
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Lui A, Chong J, Flanagan E, Abrams AW, Krysko KM, Arikan B, Francisco C, Rutatangwa A, Waubant E, Ziaei A.
Mult Scler Relat Disord. 2021 Sep 4;56:103253. doi: 10.1016/j.msard.2021.103253. Online ahead of print.
PMID: 34517190
4.
An optimized MP2RAGE sequence for studying both brain and cervical spinal cord in a single acquisition at 3T. Forodighasemabadi A, Rasoanandrianina H, El Mendili MM, Guye M, Callot V.
Magn Reson Imaging. 2021 Sep 10:S0730-725X(21)00141-7. doi: 10.1016/j.mri.2021.08.011. Online ahead of print.
PMID: 34517015
5.
Carbohydrate and lipid metabolism in multiple sclerosis: Clinical implications for etiology, pathogenesis, diagnosis, prognosis, and therapy. Pashaei S, Mohammadi P, Yarani R, Haghgoo SM, Emami Aleagha MS.
Arch Biochem Biophys. 2021 Sep 10:109030. doi: 10.1016/j.abb.2021.109030. Online ahead of print.
PMID: 34517010 Review.
6.
Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review. Reddy RA, Benerji TS, Shanker K, Prasad PJ, Perumal V, Kumar BH.
Eur J Pharmacol. 2021 Sep 10:174492. doi: 10.1016/j.ejphar.2021.174492. Online ahead of print.
PMID: 34516952 Review.
7.
In Vitro and In Vivo Investigation of S1PR1 Expression in the Central Nervous System Using [3H]CS1P1 and [11C]CS1P1. Jiang H, Joshi S, Liu H, Mansor S, Qiu L, Zhao H, Whitehead T, Gropler RJ, Wu GF, Cross AH, Benzinger TLS, Shoghi KI, Perlmutter JS, Tu Z.
ACS Chem Neurosci. 2021 Sep 13. doi: 10.1021/acschemneuro.1c00492. Online ahead of print.
PMID: 34516079
8.
Proinflammatory CD20+ T cells are differentially affected by MS therapeutics. Quendt C, Ochs J, Häusser-Kinzel S, Häusler D, Weber MS.
Ann Neurol. 2021 Sep 13. doi: 10.1002/ana.26216. Online ahead of print.
PMID: 34516013
9.
Frequency of diencephalic syndrome in NMOSD. Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A.
Acta Neurol Belg. 2021 Sep 13. doi: 10.1007/s13760-021-01792-1. Online ahead of print.
PMID: 34515964
10.
[Clinical monitoring of multiple sclerosis patients by means of digital technology, a field in the midst of a revolution]. Midaglia L, Sastre-Garriga J, Montalban X.
Rev Neurol. 2021 Sep 1;73(6):210-218. doi: 10.33588/rn.7306.2021136.
PMID: 34515334 Review. Spanish.
11.
VLA-4 as a Central Target for Modulating Neuroinflammatory Disorders. Jurberg AD, Chaves B, Pinho LG, da Silva JHM, Savino W, Cotta-de-Almeida V.
Neuroimmunomodulation. 2021 Sep 2:1-9. doi: 10.1159/000518721. Online ahead of print.
PMID: 34515173 Review.
12.
Factors Affecting Energy Metabolism and Prognosis in Patients with Amyotrophic Lateral Sclerosis. Kurihara M, Bamba S, Yasuhara S, Itoh A, Nagao T, Nakanishi N, Nakamura R, Ogawa N, Kitamura A, Yamakawa I, Kim H, Sanada M, Urushitani M, Sasaki M.
Ann Nutr Metab. 2021 Aug 24;77(4):236-243. doi: 10.1159/000518908. Online ahead of print.
PMID: 34515052
13.
Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms. Beltran-Beltran V, Benetó N, Lapeña-Luzón T, Rodríguez LR, Pallardó FV, Gonzalez-Cabo P.
Curr Protein Pept Sci. 2021 Sep 9. doi: 10.2174/1389203722666210910110126. Online ahead of print.
PMID: 34514988
14.
Considerations regarding noncredible performance in the neuropsychological assessment of patients with multiple sclerosis: A case series. Sanborn V, Lace J, Gunstad J, Galioto R.
Appl Neuropsychol Adult. 2021 Sep 11:1-10. doi: 10.1080/23279095.2021.1971229. Online ahead of print.
PMID: 34514920
15.
B cells: more than just for antibodies in SARS-CoV-2 vaccine responses. Paley MA, Kim AHJ.
Lancet Rheumatol. 2021 Sep 7. doi: 10.1016/S2665-9913(21)00280-0. Online ahead of print.
PMID: 34514435 Free PMC article. No abstract available.
16.
Sex-specific signatures of intrinsic hippocampal networks and regional integrity underlying cognitive status in multiple sclerosis. Ciolac D, Gonzalez-Escamilla G, Radetz A, Fleischer V, Person M, Johnen A, Landmeyer NC, Krämer J, Muthuraman M, Meuth SG, Groppa S.
Brain Commun. 2021 Aug 23;3(3):fcab198. doi: 10.1093/braincomms/fcab198. eCollection 2021.
PMID: 34514402 Free PMC article.
17.
Mobile health (mHealth) usage, barriers, and technological considerations in persons with multiple sclerosis: a literature review. Gromisch ES, Turner AP, Haselkorn JK, Lo AC, Agresta T.
JAMIA Open. 2020 Dec 15;4(3):ooaa067. doi: 10.1093/jamiaopen/ooaa067. eCollection 2021 Jul.
PMID: 34514349 Free PMC article. Review.
18.
A Multidisciplinary Approach in Prenatal Diagnosis of TSC With Cardiac Rhabdomyoma as the Initial Symptom. Qi Y, Ding H, Huang Y, Zeng Y, Yu L, Liu L, Zhang Y, Yin A.
Front Pediatr. 2021 Aug 27;9:628238. doi: 10.3389/fped.2021.628238. eCollection 2021.
PMID: 34513752 Free PMC article.
19.
Prophylactic and Therapeutic Effects of MOG-Conjugated PLGA Nanoparticles in C57Bl/6 Mouse Model of Multiple Sclerosis. Gholamzad M, Baharlooi H, Shafiee Ardestani M, Seyedkhan Z, Azimi M.
Adv Pharm Bull. 2021 May;11(3):505-513. doi: 10.34172/apb.2021.058. Epub 2020 Jul 26.
PMID: 34513625 Free PMC article.
20.
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O’Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P.
Front Immunol. 2021 Aug 26;12:718895. doi: 10.3389/fimmu.2021.718895. eCollection 2021.
PMID: 34512642 Free PMC article.
2021 September 12
1.
Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation. Cristiano E, Abad P, Becker J, Carrá A, Correale J, Flores J, Fruns M, Garcea O, Garcia Bónitto J, Gracia F, Hamuy F, Navas C, Patrucco L, Rivera V, Velazquez M, Rojas JI.
J Neurol Sci. 2021 Sep 8;429:118072. doi: 10.1016/j.jns.2021.118072. Online ahead of print.
PMID: 34509134
2.
Disability and life satisfaction in neurological disorders: The role of depression and perceived cognitive difficulties. Gandy M, Heriseanu AI, Dudeney J, Bisby MA, Scott AJ, Fisher A, Hathway T, Karin E, Titov N, Dear BF.
Gen Hosp Psychiatry. 2021 Sep 2;73:16-23. doi: 10.1016/j.genhosppsych.2021.08.013. Online ahead of print.
PMID: 34508992
3.
Dosing schedules for Ofatumumab in multiple sclerosis: Overegging the pudding. Avasarala J, Olson PA.
Mult Scler Relat Disord. 2021 Sep 4;56:103250. doi: 10.1016/j.msard.2021.103250. Online ahead of print.
PMID: 34508965 No abstract available.
4.
MTANS: Multi-Scale Mean Teacher Combined Adversarial Network with Shape-Aware Embedding for Semi-Supervised Brain Lesion Segmentation. Chen G, Ru J, Zhou Y, Rekik I, Pan Z, Liu X, Lin Y, Lu B, Shi J.
Neuroimage. 2021 Sep 8:118568. doi: 10.1016/j.neuroimage.2021.118568. Online ahead of print.
PMID: 34508895
5.
Characteristics of mucosal-associated invariant T cells and their roles in immune diseases. Chiba A, Murayama G, Miyake S.
Int Immunol. 2021 Sep 11:dxab070. doi: 10.1093/intimm/dxab070. Online ahead of print.
PMID: 34508634
6.
Multiple sclerosis and its impact on dental care. Patel J, Prasad R, Bryant C, Connolly H, Teasdale B, Moosajee S.
Br Dent J. 2021 Sep;231(5):281-286. doi: 10.1038/s41415-021-3333-0. Epub 2021 Sep 10.
PMID: 34508197
2021 September 11
1.
Current uses, emerging applications, and clinical integration of artificial intelligence in neuroradiology. Fiani B, Pasko KBD, Sarhadi K, Covarrubias C.
Rev Neurosci. 2021 Sep 10. doi: 10.1515/revneuro-2021-0101. Online ahead of print.
PMID: 34506699
2.
Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. Sampedro F, Kulisevsky J.
J Neuroimaging. 2021 Sep 10. doi: 10.1111/jon.12930. Online ahead of print.
PMID: 34506674
3.
Serum IFNα2 measured by single-molecule array associates with systemic disease manifestations in Sjögren’s syndrome. Huijser E, Göpfert J, Brkic Z, van Helden-Meeuwsen CG, Jansen S, Mandl T, Olsson P, Schrijver B, Schreurs MWJ, van Daele PLA, Dik WA, Versnel MA.
Rheumatology (Oxford). 2021 Sep 10:keab688. doi: 10.1093/rheumatology/keab688. Online ahead of print.
PMID: 34505866
4.
Comparative effectiveness of dimethyl fumarate in Multiple Sclerosis. Bosco-Lévy P, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef O, Lignot S, Diez P, Abouelfath A, Lassalle R, Blin P, Droz-Perroteau C.
Br J Clin Pharmacol. 2021 Sep 9. doi: 10.1111/bcp.15071. Online ahead of print.
PMID: 34505304
5.
The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis. Asha MZI, Al-Asaad Y, Khalil SFH.
IBRO Neurosci Rep. 2021 Aug 27;11:103-111. doi: 10.1016/j.ibneur.2021.08.003. eCollection 2021 Dec.
PMID: 34505112 Free PMC article. Review.
6.
Emerging deep learning techniques using magnetic resonance imaging data applied in multiple sclerosis and clinical isolated syndrome patients (Review). Kontopodis EE, Papadaki E, Trivizakis E, Maris TG, Simos P, Papadakis GZ, Tsatsakis A, Spandidos DA, Karantanas A, Marias K.
Exp Ther Med. 2021 Oct;22(4):1149. doi: 10.3892/etm.2021.10583. Epub 2021 Aug 9.
PMID: 34504594 Free PMC article. Review.
7.
The Role of Hemoglobin Subunit Delta in the Immunopathy of Multiple Sclerosis: Mitochondria Matters. Derakhshani A, Safarpour H, Abdoli Shadbad M, Hemmat N, Leone P, Asadzadeh Z, Pashazadeh M, Baradaran B, Racanelli V.
Front Immunol. 2021 Aug 24;12:709173. doi: 10.3389/fimmu.2021.709173. eCollection 2021.
PMID: 34504491 Free PMC article.
8.
Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Tobin WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, Tosakulwong N, Parisi JEE, Metz I, Frischer JM, Lassmann H, Brück W, Linbo L, Lucchinetti CF.
Neurology. 2021 Sep 9:10.1212/WNL.0000000000012782. doi: 10.1212/WNL.0000000000012782. Online ahead of print.
PMID: 34504026
9.
Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Brown C, McKee C, Halassy S, Kojan S, Feinstein DL, Chaudhry GR.
Stem Cell Res Ther. 2021 Sep 9;12(1):499. doi: 10.1186/s13287-021-02563-8.
PMID: 34503569
10.
The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis. Saridas F, Tezcan Unlu H, Cecener G, Egeli U, Sabour Takanlou M, Sabour Takanlou L, Tunca B, Zarifoglu M, Turan OF, Taskapilioglu O.
Neurol Res. 2021 Sep 10:1-7. doi: 10.1080/01616412.2021.1975221. Online ahead of print.
PMID: 34503396
11.
Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. Warmerdam E, Romijnders R, Geritz J, Elshehabi M, Maetzler C, Otto JC, Reimer M, Stuerner K, Baron R, Paschen S, Beyer T, Dopcke D, Eiken T, Ortmann H, Peters F, Recke FV, Riesen M, Rohwedder G, Schaade A, Schumacher M, Sondermann A, Maetzler W, Hansen C.
Sensors (Basel). 2021 Aug 30;21(17):5833. doi: 10.3390/s21175833.
PMID: 34502726
12.
A Preliminary Investigation of the Effects of Obstacle Negotiation and Turning on Gait Variability in Adults with Multiple Sclerosis. Weed L, Little C, Kasser SL, McGinnis RS.
Sensors (Basel). 2021 Aug 28;21(17):5806. doi: 10.3390/s21175806.
PMID: 34502697
13.
NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome. Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A.
Int J Mol Sci. 2021 Sep 1;22(17):9520. doi: 10.3390/ijms22179520.
PMID: 34502425 Review.
14.
Oligodendrocyte-Specific Deletion of FGFR1 Reduces Cerebellar Inflammation and Neurodegeneration in MOG35-55-Induced EAE. Rajendran R, Rajendran V, Giraldo-Velasquez M, Megalofonou FF, Gurski F, Stadelmann C, Karnati S, Berghoff M.
Int J Mol Sci. 2021 Aug 31;22(17):9495. doi: 10.3390/ijms22179495.
PMID: 34502405
15.
Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis. Ferrari D, Casciano F, Secchiero P, Reali E.
Int J Mol Sci. 2021 Aug 31;22(17):9449. doi: 10.3390/ijms22179449.
PMID: 34502368 Review.
16.
The Level of Stress and Coping Strategies in Patients with Multiple Sclerosis and Their Relationships with the Disease Course. Kotas R, Nowakowska-Kotas M, Budrewicz S, Pokryszko-Dragan A.
J Clin Med. 2021 Aug 30;10(17):3916. doi: 10.3390/jcm10173916.
PMID: 34501362
17.
Gender-Related Differences in Prodromal Multiple Sclerosis Characteristics: A 7-Year Observation Study. Perwieniec J, Podwójcic K, Maluchnik M, Szeląg M, Walkiewicz D, Zakrzewski M, Droździkowska A, Kamiński B, Zasybska A, Wnuk M, Słowik A, Rejdak K.
J Clin Med. 2021 Aug 26;10(17):3821. doi: 10.3390/jcm10173821.
PMID: 34501269
18.
An Overview of Peptide-Based Molecules as Potential Drug Candidates for Multiple Sclerosis. Del Gatto A, Saviano M, Zaccaro L.
Molecules. 2021 Aug 28;26(17):5227. doi: 10.3390/molecules26175227.
PMID: 34500662 Review.
19.
ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo. Stepanovska Tanturovska B, Zivkovic A, Imeri F, Homann T, Kleuser B, Stark H, Huwiler A.
Molecules. 2021 Aug 24;26(17):5134. doi: 10.3390/molecules26175134.
PMID: 34500564